Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis. 2018 Sep 26;: Authors: Solanky D, Pardi DS, Loftus EV, Khanna S Abstract Background: Inflammatory bowel disease (IBD) is an independent risk factor for Clostridium difficile infection (CDI), and CDI often precipitates IBD exacerbation. Because CDI cannot be distinguished clinically from an IBD exacerbation, management is difficult. We aimed to assess factors associated with adverse outcomes in IBD with CDI, including the role of escalating or de-escalating IBD therapy…

Read More

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished.

Related Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017 May 01;23(5):E26-E37 Authors: Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG Abstract Background: Induction treatment of mild-to-moderate Crohn’s disease is controversial. Purpose: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn’s disease. Data sources: We identified randomized controlled trials from…

Read More

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM.

Related Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM. Inflamm Bowel Dis. 2017 May 01;23(5):E25 Authors: PMID: 30052984 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30052984?dopt=Abstract

Read More

Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis.

Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018 Jun 29;: Authors: Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PD, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD, Clinical Research Alliance of the Crohn’s and Colitis Foundation Abstract BACKGROUND & AIMS: Parenteral methotrexate induces…

Read More

Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.

Related Articles Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. Dig Dis Sci. 2018 Jun 27;: Authors: Vedamurthy A, Xu L, Luther J, Colizzo F, Garber JJ, Khalili H, Ananthakrishnan AN Abstract BACKGROUND: Requirement for hospitalization in ulcerative colitis (UC) is a marker of severity of disease. However, the paradigm of when to escalate therapy in such patients and the benefits of early immunomodulator initiation is less well established. AIM: To examine the benefits of early therapy escalation in immunosuppression-naïve patients hospitalized with severe ulcerative colitis responsive…

Read More

Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry.

Related Articles Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry. Am J Gastroenterol. 2018 May 01;: Authors: Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M,…

Read More

Budesonide Suppositories are Effective and Safe for Treating Acute Ulcerative Proctitis.

Related Articles Budesonide Suppositories are Effective and Safe for Treating Acute Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2018 Apr 24;: Authors: Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, Abdulkhakov S, Lozynskyy Y, Mostovoy Y, Soloviev K, Dorofeyev AE, Vieth M, Stiess M, Greinwald R, Mohrbacher R, Siegmund B Abstract BACKGROUND & AIMS: Though proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine…

Read More

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease.

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR Abstract Background and Aims: Vedolizumab (VDZ) is effective for Crohn’s disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used…

Read More

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.

Related Articles Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. J Crohns Colitis. 2018 Apr 06;: Authors: Kevans D, Murthy S, Mould DR, Silverberg MS Abstract Background and Aims: A significant proportion of patients with corticosteroid-refractory acute ulcerative colitis [UC] fail therapy. We aimed to assess the pharmacokinetics [PK] of infliximab [IFX] in patients with corticosteroid-refractory acute UC and determine the association between induction IFX PK and short- and long-term therapy outcome. Methods: A population PK model was developed using data from…

Read More

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation.

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018 Apr 05;: Authors: Moninuola OO, Milligan W, Lochhead P, Khalili H Abstract BACKGROUND: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. AIM: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn’s disease (CD) and ulcerative colitis…

Read More
<< Go Back